This is a working overview of RP-HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
| Property | Value | Notes |
|---|---|---|
| Solubility | Freely soluble in water | Also in aqueous buffers |
| Typical purity (HPLC) | 95 percent or higher | Lot-dependent |
| Dry powder storage | Minus 20 degrees Celsius | Sealed, dry, protected from light |
| Solution storage | 2 to 8 degrees Celsius | Short-term use |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF |
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
=== Fluid replacement === The amount of fluid replaced depends on the estimated degree of dehydration. If dehydration is so severe as to cause shock (severely decreased blood pressure with insufficient blood supply to the body's organs), or a depressed level of consciousness, rapid infusion of saline (1 liter for adults, 10 mL/kg in repeated doses for children) is recommended to restore circulating volume. Slower rehydration based on calculated water and sodium shortage may be possible if the dehydration is moderate, and again saline is the recommended fluid. Very mild ketoacidosis with no associated vomiting and mild dehydration may be treated with oral rehydration and subcutaneous rather than intravenous insulin under observation for signs of deterioration. Normal saline (0.9% saline) has generally been the fluid of choice. There have been a few small trials looking at balanced fluids with few differences. A special but unusual consideration is cardiogenic shock, where the blood pressure is decreased not due to dehydration but due to the inability of the heart to pump blood through the blood vessels. This situation requires ICU admission, monitoring of the central venous pressure (which requires the insertion of a central venous catheter in a large upper body vein), and the administration of medication that increases the heart pumping action and blood pressure.
== Common SNPs in BDNF gene == BDNF has several known single nucleotide polymorphisms (SNP), including, but not limited to, rs6265, C270T, rs7103411, rs2030324, rs2203877, rs2049045 and rs7124442. rs6265 is the most studied SNP in the BDNF gene.
=== Some roles in development === Since G protein–coupled receptors are known to activate Signal transduction in cells, it should not be surprising to find MC1R involved in development. As one example at the cellular level, preventing signalling by MC1R stopped erythropoiesis from proceeding from the polychromatic cell stage (poly-E in the figure) to the orthochromatic cell stage (ortho-E in the diagram). The same report showed that neutralizing antibodies to MC1R prevented phosphorylation of STAT5 by erythropoietin, and that MC2R and MC5R were also involved, as shown in their model.
Sources: en.wikipedia.org
In oxidative phosphorylation, electrons are transferred from an electron donor such as NADH to an acceptor such as O2 through an electron transport chain, releasing energy. In photophosphorylation, the energy of sunlight is used to create a high-energy electron donor which can subsequently reduce oxidized components and couple to ATP synthesis via proton translocation by the electron transport chain. Photosynthetic electron transport chains, like the mitochondrial chain, can be considered as a special case of the bacterial systems. They use mobile, lipid-soluble quinone carriers (phylloquinone and plastoquinone) and mobile, water-soluble carriers (cytochromes). They also contain a proton pump. The proton pump in all photosynthetic chains resembles mitochondrial Complex III. The commonly held theory of symbiogenesis proposes that both organelles descended from bacteria.
However, as Liebling began to make his first attempts at recovery, the filmmakers started to see potential in his journey. Shaping Last Days Here into a coherent narrative proved to be a challenge. Liebling's personality was more erratic than the documentary ultimately portrayed. "Many times we had to finesse the rapid shifts in Bobby's life so the viewer wouldn't be left confused. Over the three years we were shooting, we saw the many different faces of Bobby Liebling. The delusional crack-smoking hustler, the arrogant '70s rock star, and the really cool loveable uncle. When boiling the footage down to 90 minutes, we really wanted to exemplify a balance of those personalities. That balance is sometimes tough to maintain," stated Fenton.
S. mutilans, like other centipedes, is a predator that kills by injecting venom into its prey. Venom is injected to immobilize and break down internal tissues. Venoms of Scolopendridae, including Scolopendra mutilans, contain neurotoxins, which are suspected to be a significant fast-acting component in venoms of many centipedes. This species mainly feeds on live animals; plant materials are occasionally consumed but its consumption is considered negligible. To get hold of the prey, this centipede grabs prey with its anterior legs, and typically envenomates prey by stabbing it using its forcipules. Little quantitative ecological and behavioural work was done for centipedes. Some studies, however, have found that centipedes are highly selective and tend to strike at the head or thorax instead of the abdomen. If the bite was made on the abdomen, the centipede would usually reposition the prey and strike again on the head or thorax. Venom availability has a significant effect on predatory response. Returning to their normal attack rate after venom extraction takes more time when facing larger prey. Research on these behaviours has suggested that the reason for centipedes to reposition their prey is to enhance the speed where neurotoxins in the venom arrive at the thoracic ganglia, where it controls limb movement or the brain. This explanation was based on the position of such ganglia locating on the abdominal side (i.e.
Sources: en.wikipedia.org
==== Salatory conduction in myelin ==== In many cases of neurapraxia, damage to the myelin sheath occurs, disrupting salatory conduction and disrupting the propagation of impulses along the nodes of Ranvier. Damage to myelin can slow or block conduction, leading to a temporary loss of motor coordination and sensory function until remyelination occurs.
=== ARDS in COVID-19 === Studies have found that aviptadil may be beneficial for severely ill patients with COVID-19 related ARDS. ACTIV-3, a trial examining aviptadil acetate (Zyesami), is recruiting patients as of July 2, 2021. A separate trial is examining inhaled aviptadil for patients with high risk for ARDS, is ongoing as of May 21, 2021. A trial for intravenous aviptadil for the same indication concluded in February 2021. US-Israeli NeuroRx Inc partnered with Relief Therapeutics to develop aviptadil in the United States. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to aviptadil for the treatment of respiratory distress in COVID-19. In September 2020, NeuroRX submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care. Jan 2021: Zuventus healthcare Ltd seeks approval for aviptadil from India's drug controller for emergency use in COVID-19 treatment. Mumbai's Zuventus Healthcare Ltd. has got the nod to conduct Phase 3 clinical trials of aviptadil injectable formulation. The SEC noted that Zuventus had presented revised Phase 3 clinical trial protocol before the committee, and after "detailed deliberation", it recommended grant of permission of Phase 3 trials with the drug. May 2021: NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (aviptadil-acetate) and Submits Emergency Use Authorization Application to USFDA to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure.
In 1887 Johannes Wislicenus published a study of stereoisomerism in unsaturated compounds. Groth made a systematic classification of minerals based on their chemical composition and crystal structure and published his results in his 5-volume Chemische Kristallographie in 1906–1919, which contained crystalline morphology and physical property data on nearly 10,000 substances. In 1913 Walter Wahl summarised the known connections between chemical composition and crystalline form as isomorphism (Mitscherlich), morphotropism (Groth), and enantiomorphism (Pasteur and van 't Hoff). In his preface to Andreas Fock's An introduction to chemical crystallography Pope summarised the state of chemical crystallography in 1895 as follows:
=== 16 April === Ukraine and Russia conducted an Orthodox Easter prisoner swap. Some one hundred and thirty Ukrainian POWs were returned to Ukraine in exchange for an unknown number of Russian soldiers. Ukrainian officials said that the remains of some eighty-two deceased Ukrainian soldiers were retrieved from territory controlled by Russia. Chinese defense minister Li Shangfu met with Putin amid reports of Ukrainian forces finding an increasing number of Chinese components in Russian weapons, and leaked classified documents from the United States about China's alleged plans to covertly supply Russia with weapons.
Sources: en.wikipedia.org
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.
Freeze-dried material is kept frozen, often at minus 20 degrees Celsius, and protected from light and moisture. Dissolved peptide is refrigerated for short-term use. Repeated freeze-thaw cycles are avoided.
A certificate of analysis typically lists purity by HPLC, the confirmed mass, appearance, and sometimes water or counter-ion content. It documents results for a specific batch. Details vary by supplier.
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.